Abstract

Leiomyosarcoma is a smooth muscle tissue cancer. It is a rare cancer. It accounts for 5–10% of soft tissue sarcoma and can recur in later stage of life. Leiomyosarcoma is highly unpredictable. This is a resistant type of cancer and for long time it can remain in the dormant state. Uterine leiomyosarcoma is a rare, 3 - 9% of all uterine cancers, and about 70% of uterine sarcomas. A uterine leiomyosarcoma diagnosis is confirmed by doing histological examination of mass removed by myomectomy or hysterectomy. There are many treatment options available for metastatic leiomyosarcoma of the uterus such as Surgical resection (hysterectomy) is standard treatment for patients with localized leiomyosarcoma, Adjuvant chemotherapy- for early-stage disease is controversial, Bilateral salpingo-oophorectomy -in peri and postmenopausal patients, Lymphadenectomy-if there is evidence of concerning lymph nodes, Radiotherapy is indicated for palliative care, Adjuvant chemotherapy for metastatic / recurrent tumors, Immunotherapy for high uterine leiomyosarcoma and Hormonal therapy may be an option.

• 1.   Mayo Clinic. Leiomyosarcoma [Internet]. 2024 [cited 2025 Jul 17].
• 2.   Singh Z, LMS A. Leiomyosarcoma: a rare soft tissue cancer arising from multiple organs. J Cancer Res Pract [Internet]. 2017 [cited 2025 Jul 17].
• 3.   George S, Serrano C, Hensley ML, Ray-Coquard I. Soft tissue and uterine leiomyosarcoma. J Clin Oncol. 2018;36(2):144-150.
• 4.   Roberts ME, Aynardi JT, Chu CS. Uterine leiomyosarcoma: a review of the literature and update on management options. Gynecol Oncol. 2018;151(3):562-572.
• 5.   George S, Serrano C, Hensley ML, Ray-Coquard I. Soft tissue and uterine leiomyosarcoma. J Clin Oncol. 2018;36(2):144-150.
• 6.   Penn Medicine. Leiomyosarcoma [Internet]. [cited 2025 Jul 17].
• 7.   Bonvalot S, Miceli R, Berselli M, Causeret S, Colombo C, Mariani L, et al. Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control. Ann Surg Oncol. 2010;17(6):1507-1514.
• 8.   Seagle BL, Sobecki-Rausch J, Strohl AE, Shilpi A, Grace A, Shahabi S. Prognosis and treatment of uterine leiomyosarcoma: a National Cancer Database study. Gynecol Oncol. 2017;145(1):61-70.
• 9.   von Mehren M, Kane JM, Agulnik M, Bui MM, Carr-Ascher J, Choy E, et al. Soft tissue sarcoma, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(7):815-833.
• 10.   Gronchi A, De Paoli A, Dani C, Merlo DF, Quagliuolo V, Grignani G, et al. Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group. Eur J Cancer. 2014;50(4):784-792.
• 11.   Kraybill WG, Harris J, Spiro IJ, Ettinger DS, DeLaney TF, Blum RH, et al. Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. Cancer. 2010;116(19):4613-4621.
• 12.   Loong HH, Wong KH, Tse T. Controversies and consensus of neoadjuvant chemotherapy in soft-tissue sarcomas. ESMO Open. 2018;3(Suppl 1):e000293.

Data Sharing Statement

Funding